Market Research Report
ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||568463|
|Published||Content info||87 Pages
Delivery time: 1-2 business days
|ASIA PACIFIC BOTANICAL & PLANT DERIVATIVE DRUG MARKET FORECAST 2018-2026|
|Published: February 12, 2018||Content info: 87 Pages||
The Asia-Pacific botanical and plant derivative drug market is predicted to rise at 9.01% CAGR over the forecast period of 2018-2026. The market is driven by the rising investment of pharmaceutical companies and increased integration of plant-derived drugs in the market.
The market is segmented on the basis of plant-derived drug type, products, and therapeutic applications. These drugs are less toxic in nature as compared to traditional methods. Indian botanical and plant derivative drug market is expected to exhibit the highest growth over the forecast period. A strong demand for Ayurvedic, Unani and Siddha products have contributed considerably to the leading plant-derivative drug manufacturing companies to gain a strong foothold in this region. Also, major steps have been taken towards the adoption of botanical and plant derivative drugs by the governments of other Asia-Pacific countries like Japan, South Korea, China, Australia, etc.
Abbott Pharmaceuticals, GlaxoSmithKline, Glenmark Pharmaceuticals Ltd, Piramal Phytocare Ltd. Bayer Healthcare Llc, Pfizer international, Novartis International Ag, Ranbaxy Laboratories Ltd (Acquired By Sun Pharmaceuticals Ltd), Lupin Ltd, etc. are some of the well-known companies in the market.